PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsFenofibrate
Lipidil, Pravafenix(fenofibrate)
Antara, Cholib, Fenofibrate, Lipofen, Pravafenix (fenofibrate) is a small molecule pharmaceutical. Fenofibrate was first approved as Lipidil on 1993-12-31. It is used to treat coronary artery disease, hypercholesterolemia, hyperlipoproteinemias, and hypertriglyceridemia in the USA. It has been approved in Europe to treat dyslipidemias. The pharmaceutical is active against peroxisome proliferator-activated receptor alpha. In addition, it is known to target chloride channel protein 1 and fatty acid-binding protein, liver.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
nutritional and metabolic diseasesD009750
Trade Name
FDA
EMA
Antara, Fenofibrate, Lipofen, Zuragard (discontinued: Antara, Fenofibrate, Fenoglide, Lipofen, Tricor, Triglide)
Combinations
Chloraprep one-step, Chloraprep triple swabstick, Duraprep, Prevantics maxi swabstick, Soluprep
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Fenofibrate
Tradename
Company
Number
Date
Products
LIPOFENCipher PharmaceuticalsN-021612 RX2006-01-11
2 products, RLD, RS
ANTARA (MICRONIZED)Lupin ResearchN-021695 RX2004-11-30
2 products, RLD, RS
Show 8 discontinued
Chlorhexidine gluconate
+
Isopropyl alcohol
Tradename
Company
Number
Date
Products
SOLUPREP S3MN-208288 OTC2018-08-08
1 products, RLD, RS
CHLORAPREP ONE-STEPBDN-020832 OTC2000-07-14
1 products, RLD, RS
CHLORAPREP WITH TINTBDN-020832 OTC2005-05-03
1 products, RLD, RS
CHLORAPREP ONE-STEP FREPPBDN-020832 OTC2002-04-26
1 products, RLD, RS
CHLORAPREP ONE-STEPBDN-020832 OTC2003-08-20
1 products, RLD, RS
CHLORAPREP WITH TINTBDN-020832 OTC2006-04-03
1 products, RLD, RS
CHLORAPREP ONE-STEPBDN-020832 OTC2006-11-21
1 products, RLD, RS
CHLORAPREP WITH TINTBDN-020832 OTC2006-10-10
1 products, RLD, RS
CHLORAPREP ONE-STEPBDN-020832 OTC2008-10-23
1 products, RLD, RS
CHLORAPREP ONE-STEP SEPPBDN-021555 OTC2002-10-07
1 products, RLD, RS
Show 5 marketed
Isopropyl alcohol
Tradename
Company
Number
Date
Products
ZURAGARDZurex PharmaN-210872 OTC2019-04-26
1 products, RLD, RS
Iodine povacrylex
+
Isopropyl alcohol
Tradename
Company
Number
Date
Products
DURAPREP3MN-021586 OTC2006-09-29
2 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
antaraNew Drug Application2024-08-20
fenofibrateANDA2025-02-20
fenoglideNew Drug Application2011-05-13
lipofenNew Drug Application2021-09-21
tricorNew Drug Application2024-11-14
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Fenofibrate, Antara (Micronized), Lupin
93144472033-05-31DPU-1447, U-1448
80262812025-04-22U-1447, U-1448
Fenofibrate, Fenoglide, Salix
76589442024-12-09DP
81241252024-10-01DPU-1234
84810782024-10-01DPU-1416
91738472024-10-01DP
ATC Codes
C: Cardiovascular system drugs
C10: Lipid modifying agents
C10A: Lipid modifying agents, plain
C10AB: Fibrates, lipid modifying drugs, plain
C10AB05: Fenofibrate
C10AB11: Choline fenofibrate
C10B: Lipid modifying agents, combinations
C10BA: Combinations of various lipid modifying agents
C10BA03: Pravastatin and fenofibrate
C10BA04: Simvastatin and fenofibrate
C10BA09: Rosuvastatin and fenofibrate
C10BA12: Pravastatin, ezetimibe and fenofibrate
HCPCS
No data
Clinical
Clinical Trials
336 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
DyslipidemiasD0501716131611748
HypertriglyceridemiaD015228EFO_000421115910631
HyperlipidemiasD006949EFO_0003774E78.512148530
HyperlipoproteinemiasD0069511127323
InfectionsD007239EFO_0000544247821
Type 2 diabetes mellitusD003924EFO_0001360E11265618
Diabetes mellitusD003920EFO_0000400E08-E13244818
Surgical wound infectionD0135301245416
Metabolic syndromeD024821EFO_0000195E88.810313815
Communicable diseasesD003141145515
Show 57 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients141621
Non-alcoholic fatty liver diseaseD065626EFO_0003095K75.811337
Fatty liverD005234EFO_00039341337
Liver diseasesD008107EFO_0001421K70-K77336
InflammationD007249MP_0001845123
NeoplasmsD009369C801113
Weight lossD015431112
OverweightD050177E66.322
Multiple myelomaD009101C90.0112
Plasma cell neoplasmsD054219112
Show 27 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Bacterial infectionsD001424A4911
Gram-negative bacterial infectionsD01690511
InfertilityD007246EFO_000054511
Rotavirus infectionsD01240011
Depressive disorderD003866EFO_1002014F32.A11
Carcinoma in situD002278D09.911
Uterine cervical dysplasiaD002578EFO_1000910N8711
Chronic renal insufficiencyD051436N1811
Renal insufficiencyD051437N1911
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Diabetes complicationsD04890922
Vascular diseasesD014652EFO_0004264I7722
RadiodermatitisD011855L5822
MalnutritionD044342EFO_0008572E40-E4622
ThrombosisD01392722
Myofascial pain syndromesD009209EFO_100105422
Bites and stingsD00173322
SchizophreniaD012559EFO_0000692F2011
CytokinesisD04874911
Vitamin d deficiencyD014808EFO_0003762E5511
Show 41 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameFenofibrate
INNfenofibrate
Description
Fenofibrate is a chlorobenzophenone that is (4-chlorophenyl)(phenyl)methanone substituted by a [2-methyl-1-oxo-1-(propan-2-yloxy)propan-2-yl]oxy group at position 1 on the phenyl ring. It has a role as an antilipemic drug, an environmental contaminant, a xenobiotic and a geroprotector. It is a chlorobenzophenone, a member of monochlorobenzenes, an aromatic ether and an isopropyl ester. It is functionally related to a benzophenone.
Classification
Small molecule
Drug classantihyperlipidemics (clofibrate type)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC(C)OC(=O)C(C)(C)Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1
Identifiers
PDB
CAS-ID49562-28-9
RxCUI
ChEMBL IDCHEMBL672
ChEBI ID5001
PubChem CID3339
DrugBankDB01039
UNII IDU202363UOS (ChemIDplus, GSRS)
Target
Agency Approved
PPARA
PPARA
Organism
Homo sapiens
Gene name
PPARA
Gene synonyms
NR1C1, PPAR
NCBI Gene ID
Protein name
peroxisome proliferator-activated receptor alpha
Protein synonyms
Nuclear receptor subfamily 1 group C member 1, peroxisome proliferative activated receptor, alpha
Uniprot ID
Mouse ortholog
Ppara (19013)
peroxisome proliferator-activated receptor alpha (P23204)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
£
Tricor Elan Corporation
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tricor AbbVie
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Fenofibrate
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 63,259 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
26,509 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use